RICTOR and breast cancer: Rictor depletion from HER2-amplified human breast cancer cell lines or in genetically engineered transgenic mouse models of HER2-amplified breast cancer demonstrates the requirement for Rictor/mTORC2 signaling in tumor formation, tumor cell survival and resistance to HER2-targeted therapy [14].